苯达莫司汀联合伊沙佐米对MM患者sVCAM-1、β2-MG和超声参数的影响

doi:10.7517/issn.1674-0475.220409

摘要/Abstract

摘要： 本文探究苯达莫司汀联合伊沙佐米治疗多发性骨髓瘤（MM）患者sVCAM-1、β2-MG的超声评估价值。选取100例多发性骨髓瘤患者为研究对象，随机分为对照组（50例）和研究组（50例）。两组均进行对症治疗，对照组给予地塞米松+苯达莫司汀，研究组给予地塞米松+苯达莫司汀+伊沙佐米。在治疗前后，两组患者均行超声检查，并检测患者sVCAM-1、β2-MG水平。治疗后，两组患者sVCAM-1、β2-MG、皮质IBS、髓质IBS、叶间动脉RI水平下降，且研究组低于对照组，肾脏体积、肾脏长度、叶间动脉PSV水平均升高，且研究组明显高于对照组（P<0.05）。与研究组治疗无效患者相比，治疗有效患者肾脏体积、肾脏长度、叶间动脉PSV水平较高，皮质IBS、髓质IBS、叶间动脉RI水平较低（P<0.05）。研究组治疗有效率明显高于对照组（P<0.05）。综上可知，多发性骨髓瘤患者经苯达莫司汀联合伊沙佐米治疗后sVCAM-1、β2-MG水平下降，临床疗效理想，同时，经联合治疗后超声参数明显变化，提示超声可用于多发性骨髓瘤患者临床疗效的评估。

关键词: 多发性骨髓瘤, 伊沙佐米, 苯达莫司汀, 可溶性血管细胞黏附分子-1, β2-微球蛋白, 超声

Abstract: This paper exploreed the value of bendamustine combined with ixazomib for sVCAM-1 and β2-MG in patients with multiple myeloma (MM). Selected 100 multiple myeloma patients as research subjects, and divided them into the control group with 50 patients and 50 patients in the study group randomly. Both the two groups were given symptomatic treatment, the control group received dexamethasone plus bendamustine, and the study group gave dexamethasone plus bendamustine plus ixazomib. Before and after treatment, the patients in both groups were examined by ultrasound, the sVCAM-1 and β2-MG levels were tested as well. After treatment, the sVCAM-1, β2-MG, cortical IBS, medulla IBS, interlobe artery RI levels decreased, and the study group was lower than the control group. The kidney volume, kidney length, interlobe artery PSV levels increased, and the study group was higher than the control group (P<0.05). Compared with the ineffective patients in the study group, the effective patients had higher levels of kidney volume, kidney length, and interlobar artery PSV, while lower cortical IBS, medulla IBS, and interlobar artery RI levels (P<0.05). The effective rate of treatment in the study group was significantly higher than that in the control group (P<0.05). To sum up, the levels of sVCAM-1 and β2-MG in patients with multiple myeloma decreased after bendamustine combined with ixazomib treatment, and the clinical efficacy was satisfactory, and the ultrasound parameters changed significantly after the combined treatment, which suggested that ultrasound can be used for evaluation of clinical efficacy in patients with multiple myeloma.

Key words: multiple myeloma, ixazomib, bendamustine, soluble vascular cell adhesion molecule-1, β2-microglobulin, ultrasound

刘敏, 余卓君, 梁艳, 黄知平, 唐元艳. 苯达莫司汀联合伊沙佐米对MM患者sVCAM-1、β2-MG和超声参数的影响[J]. 影像科学与光化学, 2022, 40(5): 1174-1178.

LIU Min, YU Zhuojun, LIANG Yan, HUANG Zhiping, TANG Yuanyan. Effects of Bendamustine Combined with Ixazomib on sVCAM-1, β2-MG and Ultrasound Parameters in MM Patients[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(5): 1174-1178.

参考文献

[1] 王中良, 邢鹏涛, 王金慧, 等. 多发性骨髓瘤中循环骨髓瘤细胞水平及临床意义[J]. 临床骨科杂志, 2022, 25(2):296-300.
[2] 杨莹, 刘卓刚, 胡荣. 伊沙佐米治疗复发/难治多发性骨髓瘤的临床疗效[J]. 现代肿瘤医学, 2021, 29(4):679-682.
[3] 宋变变, 廖爱军. 苯达莫司汀治疗复发/难治性多发性骨髓瘤的研究进展[J]. 现代肿瘤医学, 2019, 27(24):4471-4475.
[4] Castillo J J, Advani R H, Branagan A R, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia[J]. The Lancet Haematology, 2020, 7(11):e827-e837.
[5] 费晓莉, 陶黎, 熊梅, 等. IL-37、VEGF、LDH和β2-MG在多发性骨髓瘤中的表达及其临床意义[J]. 重庆医学, 2021, 50(2):275-279.
[6] 乌云, 严怀秀, 樊迪, 等. 硼替佐米治疗肾功能不全多发性骨髓瘤患者的临床疗效及对Scr、BUN和24h尿蛋白量的影响[J]. 中国病案, 2021, 22(12):109-113.
[7] 王海霞, 宋倩, 刘景萍. 彩色多普勒超声检查对乳腺癌鉴别诊断及新辅助化疗疗效评估的临床价值[J]. 临床和实验医学杂志, 2021, 20(15):1666-1669.
[8] 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订)[J]. 中华内科杂志, 2020, 59(5):341-346.
[9] Cowan A J, Green D J, Kwok M, et al. Diagnosis and management of multiple myeloma:A review[J]. The Journal of the American Medical Association, 2022, 327(5):464-477.
[10] 付彬, 谷梨花, 刘萍, 等. 伊沙佐米为基础的化疗方案治疗复发难治多发性骨髓瘤临床研究[J]. 白血病·淋巴瘤, 2021, 30(6):340-343.
[11] 鲍静, 陈晓文, 夏亮, 等. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7):782-786.
[12] 石磊, 陆敏秋, 高珊, 等. 苯达莫司汀联合化疗方案治疗复发/难治性多发性骨髓瘤的临床观察[J]. 中国医师杂志, 2021, 23(12):1822-1827.
[13] 陈延杰. 多发性骨髓瘤患者血清sICAM-1、sVCAM-1、Treg水平与预后的相关性分析[J]. 临床血液学杂志, 2021, 34(4):259-263.
[14] 姜薇, 潘亚宁, 王冬梅. 不同化疗方案对多发性骨髓瘤患者血清sICAM-1、sVCAM-1、Treg及预后的影响[J]. 临床误诊误治, 2019, 32(7):29-33.
[15] 韩少玲, 吴亚兵, 张家友, 等. 多发性骨髓瘤患者血清β2-MG、CRP和IL-6水平与临床分期的关系[J]. 河北医药, 2021, 43(3):353-356.
[16] 韩少玲, 吴亚兵, 张家友, 等. 血清LDH和β2-MG水平与多发性骨髓瘤患者预后的相关性[J]. 实用癌症杂志, 2020, 35(11):1817-1820, 1825.
[17] 王丽, 赵艳莉, 金瑄, 等. 多发性骨髓瘤患者的血清β2-MG、TNF-α、IL-6水平及其临床意义[J]. 海南医学, 2020, 31(12):1527-1529.
[18] 刘晓鹏, 黄国强, 赵小莹, 等. 半胱氨酸蛋白酶抑制剂C血游离轻链水平对多发性骨髓瘤肾损伤患者BTD治疗方案疗效的预估价值研究[J]. 山西医药杂志, 2020, 49(14):1799-1802.
[19] 胥兴丽, 原江水, 王仁峰. Cys-C、β2-M及轻链类型检测在多发性骨髓瘤肾损伤诊断中的应用[J]. 检验医学与临床, 2020, 17(23):3414-3416.
[20] 杨敏. 多发性骨髓瘤患者血清Cys-C、Urea、Scr及β2-MG水平检测及其临床意义[J]. 标记免疫分析与临床, 2019, 26(3):506-510.
[21] Huang Y P, Huang J X, Zhang P, et al. Integrated analysis of hub gene expression in multiple myeloma[J]. Journal of the Balkan Union of Oncology, 2021, 26(5):2040-2052.